Engineering of magnetic DNA nanoparticles for tumor-targeted therapy
Source abstract
Abstract
This study aims to engineer novel targeted delivery system composed of magnetic DNA nanoparticles to be effective as an efficient targeted gene therapy vehicle for tumor therapy. A polysaccharide, dextran, was chosen as the vector of plasmid DNA-encoded NK4 that acts as an HGF-antagonist and anti-angiogenic regulator for inhibitions of tumor growth, invasion, and metastasis. Spermine (Sm) was chemically introduced to the hydroxyl groups of dextran to obtain dextran-Sm. When Fe2+ solution was added to the mixture of dextran-Sm and a plasmid DNA, homogenous DNA nanoparticles were formed via chemical metal coordination bonding with average size of 230 nm. Characterization of DNA nanoparticles was performed via dynamic light scattering measurement, electrophoretic light scattering measurement, as well as transmission electron microscope. DNA nanoparticles effectively condensed plasmid DNA into nanoparticles and enhanced the stability of DNA, while significantly improved transfection efficiency in vitro and tumor accumulation in vivo. In addition, magnetic DNA nanoparticles exhibited high efficiency in antitumor therapy with regards to tumor growth as well as survival of animals evaluated in the presence of external magnetic field. We conclude that the magnetic properties of these DNA nanoparticles would enhance the tracking of non-viral gene delivery systems when administrated in vivo in a test model. These findings suggest that DNA nanoparticles effectively deliver DNA to tumor and thereby inhibiting tumor growth.
Source: openaire · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: RNA Interference and Gene Delivery · Advanced biosensing and bioanalysis techniques · Bacteriophages and microbial interactions
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (33)
Show source-provided references
1. Abdullah S, Yeo Y, Hosseinkhani H, Hosseinkhani M, Masrawa E, Ramasamy R, Rosli R, Rahman SA, Domb AJ (2010) Gene transfer into the lung by nanoparticles dextran-spermine/plasmid DNA complexes. J Biomed Biotechnol 2010:1–1010.1155/2010/284840 ↗
2. Abedini F, Ismail M, Hosseinkhani H, Azmi TI, Omar AR, Chong PP et al (2010) Toxicity evaluation of dextran-spermine polycation as a tool for gene therapy in vitro. J Cell Anim Biol 4:170–176
3. Abedini F, Hosseinkhani H, Ismail M, Omar AR, Chong PP, Domb AJ (2011a) In vitro intracellular trafficking of biodegradable nanoparticles of dextran-spermine in cancer cell lines. Int J Nanotechnol 8:712–72310.1504/IJNT.2011.041440 ↗
4. Abedini F, Ismail M, Hosseinkhani H, Azmi TI, Omar AR, Pei Pei C, Bejo MH, Domb AJ (2011b) Effects of CXCR4 siRNAs/dextran-spermine nanoparticles on CXCR4 expression and serum LDH levels in a mouse model of colorectal cancer metastasis to the liver. Cancer Manag Res 3:301–309
5. Azzam T, Eliyahu H, Shapira L, Linial M, Barenholz Y, Domb AJ (2002) Polysaccharide-oligo amine based conjugates for gene delivery. J Med Chem 45:1817–182310.1021/jm0105528 ↗
6. Hanahan D, Folkman J (1996) Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86:353–36410.1016/S0092-8674(00)80108-7 ↗
7. Harris JM, Chess RB (2003) Effect of pegylation on pharmaceuticals. Nat Rev Drug Discov 2:214–22110.1038/nrd1033 ↗
8. Holmgren L, O’Reilly MS, Folkman J (1995) Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nat Med 1:149–15310.1038/nm0295-149 ↗
9. Hosseinkhani H (2006) DNA nanoparticles for gene delivery to cells and tissue. Int J Nanotechnol 3:416–46110.1504/IJNT.2006.011172 ↗
10. Hosseinkhani H, Hosseinkhani M (2009) Biodegradable polymer-metal complexes for gene and drug delivery. Curr Drug Saf 4:79–8310.2174/157488609787354477 ↗
11. Hosseinkhani H, Tabata Y (2005) Ultrasound enhances in vivo tumor expression of plasmid DNA by PEG-introduced cationized dextran. J Control Release 108:540–55610.1016/j.jconrel.2005.08.027 ↗
12. Hosseinkhani H, Aoyama T, Ogawa O, Tabata Y (2002) Liver targeting of plasmid DNA by pullulan conjugation based on metal coordination. J Control Release 83:286–30110.1016/S0168-3659(02)00201-8 ↗
13. Hosseinkhani H, Aoyama T, Ogawa O, Tabata Y (2003) Tumor targeting of gene expression by dextran conjugation based on metal coordination. J Control Release 88:297–31210.1016/S0168-3659(02)00425-X ↗
14. Hosseinkhani H, Azzam T, Tabata Y, Domb AJ (2004) Dextran-spermine polycation: an efficient nonviral vector for in vitro and in vivo gene transfection. Gene Ther 11:194–20310.1038/sj.gt.3302159 ↗
15. Hosseinkhani H, Azzam T, Kobayashi H, Hiraoka Y, Shimokawa H, Domb AJ, Tabata Y (2006a) Combination of 3-D tissue engineered scaffold and non-viral gene enhance in vitro DNA expression of mesenchymal stem cells. Biomaterials 27:269–4278
16. Hosseinkhani H, Kushibiki T, Matsumoto K, Nakamura T, Tabata Y (2006b) Enhanced suppression of tumor growth using a combination of NK4 plasmid DNA-PEG engrafted cationized dextran complex and ultrasound. Cancer Gene Ther 13:479–48910.1038/sj.cgt.7700918 ↗
17. Hosseinkhani H, Hosseinkhani M, Khademhosseini (2006c) A Emerging applications of hydrogels and microscale technologies in drug discovery. Drug Discov 1:32–34
18. Hosseinkhani M, Hosseinkhani H, Chen YR, Subramani K (2011a) In vitro physicochemical evaluation of DNA nanoparticles. Int J Nanotechnol 8:736–74810.1504/IJNT.2011.041442 ↗
19. Hosseinkhani H, Hosseinkhani M, Chen YR, Subramani K, Domb AJ (2011b) Innovative technology of engineering magnetic DNA nanoparticles for gene therapy. Int J Nanotechnol 8:724–73510.1504/IJNT.2011.041441 ↗
20. Kircheis R, Wightman L, Schreiber A, Robitza B, Rossler V, Kursa M, Wagner (2001) Polyethylenimine/DNA complexes shielded by transferrin target gene expression to tumors after systemic application. Gene Ther 8:28–4010.1038/sj.gt.3301351 ↗
21. Kuba K, Matsumoto K, Ohnishi K, Shiratsuchi T, Tanaka M, Nakamura T (2000a) Kringle 1–4 of hepatocyte growth factor inhibits proliferation and migration of human microvascular endothelial cells. Biochem Biophys Res Commun 279:846–85210.1006/bbrc.2000.4034 ↗
22. Kuba K, Matsumoto K, Date K, Shimura H, Tanaka M, Nakamura T (2000b) HGF/NK4, a four-kringle antagonist of hepatocyte growth factor, is an angiogenesis inhibitor that suppresses tumor growth and metastasis in mice. Cancer Res 60:6737–6743
23. Kushibiki T, Matsumoto K, Nakamura T, Tabata Y (2004) Suppression of tumor metastasis by NK4 plasmid DNA released from cationized gelatin. Gene Ther 11:1205–121410.1038/sj.gt.3302285 ↗
24. Langer R, Tirrell DA (2004) Designing materials for biology and medicine. Nature 428:487–49210.1038/nature02388 ↗
25. Maemondo M, Narumi K, Saijo Y et al (2002) Targeting angiogenesis and HGF function using an adenoviral vector expressing the HGF antagonist NK4 for cancer therapy. Mol Ther 5:177–18510.1006/mthe.2002.0533 ↗
26. Mahmoudi M, Hosseinkhani H, Hosseinkhani M, Boutry S, Simchi A, Journeay WS et al (2011) Magnetic resonance imaging tracking of stem cells in vivo using iron oxide nanoparticles as a tool for the advancement of clinical regenerative medicine. Chem Rev 111:253–28010.1021/cr1001832 ↗
27. Molineux G (2003) Pegylation: engineering improved biopharmaceuticals for oncology. Pharmacotherapy 23:3S–8S10.1592/phco.23.9.3S.32886 ↗
28. O’Reilly MS, Holmgren L, Chen C, Folkman J (1996) Angiostatin induces and sustains dormancy of human primary tumors in mice. Nat Med 2:689–69210.1038/nm0696-689 ↗
29. Peppas NA, Langer R (1994) New challenges in biomaterials. Science 263:1715–172010.1126/science.8134835 ↗
30. Roberts MJ, Bentley MD, Harris JM (2002) Chemistry for peptide and protein PEGylation. Adv Drug Deliv Rev 54:459–47610.1016/S0169-409X(02)00022-4 ↗
31. Saimura M, Nagai E, Mizumoto K et al (2002) Intraperitoneal injection of adenovirus-mediated NK4 gene suppresses peritoneal dissemination of pancreatic cancer cell line AsPC-1 in nude mice. Cancer Gene Ther 9:799–80610.1038/sj.cgt.7700504 ↗
32. Sato N, Kobayashi H, Saga T, Nakamoto Y, Ishimori T, Togashi K et al (2001) Tumor targeting and imaging of intraperitoneal tumors by use of antisense oligo-DNA complexed with dendrimers and/or avidin in mice. Clin Cancer Res 7:3606–3612
33. Sim BK, MacDonald NJ, Gubish ER (2000) Angiostatin and endostatin: endogenous inhibitors of tumor growth. Cancer Metastasis Rev 19:181–19010.1023/A:1026551202548 ↗